TLDR
- Janux Therapeutics shares plummeted 41% following Phase 1 trial results for prostate cancer drug JANX007
- Trial showed 30% partial response rate and 7.9-8.9 months progression-free survival in late-stage prostate cancer patients
- Three major analysts cut price targets by 20-60% due to limited new patient data and competitive concerns
- Novartis’s Pluvicto shows superior results with 49% response rate and 11.6 months progression-free survival
- Despite crash, analysts maintain Strong Buy rating with $75.42 average target implying 122% upside
Janux Therapeutics experienced a massive selloff Tuesday after unveiling Phase 1 clinical data for its prostate cancer treatment. The biotech company lost 41% in premarket trading despite calling the results “positive.”
Janux Therapeutics, Inc., JANX
The data release for JANX007 showed anti-tumor activity in patients with metastatic castration-resistant prostate cancer. This advanced cancer has spread beyond the prostate gland to other body parts.
JANX007 works as a T-cell engager, directing immune cells to attack cancer cells expressing the PSMA protein. The Phase 1 trial demonstrated partial responses in 30% of evaluable patients. Radiographic progression-free survival measured between 7.9 and 8.9 months.
The company highlighted a “manageable safety profile” and “durable responses” in its announcement. Investors saw things differently.
Wall Street Slashes Expectations
Stifel analyst Stephan Willey dropped his price target to $38 from $46. He maintained a Buy rating but raised concerns about limited progress. The company generated minimal new patient data over the past 12 months, Willey noted.
Questions about dosing strategy and Phase 3 trial timing remain unanswered. Growing competition in the prostate cancer space adds pressure. Despite these concerns, Willey believes the selloff looks excessive given the platform’s strength.
H.C. Wainwright analyst Swayampakula Ramakanth made a steeper cut, reducing his target to $45 from $70. He kept his Buy rating but called the results “mixed.” Key efficacy endpoints deteriorated from earlier readings. JANX007 will likely need to prove itself as more data becomes available, Ramakanth said.
Clear Street analyst Kaveri Pohlman delivered the harshest assessment. She slashed her price target to $32 from $80, a 60% reduction. Pohlman cited “more pragmatic” market entry timelines while maintaining her Buy rating.
Pluvicto Sets High Bar
The comparison everyone’s making is to Novartis’s Pluvicto. The already-approved treatment posted a 49% overall response rate in later-stage trials. Its median progression-free survival reached 11.6 months.
Those numbers eclipse JANX007’s current performance. Investors want clarity on how Janux plans to compete in this crowded space.
The stock’s reaction marks a dramatic reversal from a year ago. Shares jumped double digits when early Phase 1 data showed all patients achieved at least 50% reduction in prostate-specific antigen levels.
Tuesday’s data showed some positive signals. High-quality PSA responses correlated with treatment durability. But investors needed more substantial progress after waiting over a year.
Market Still Optimistic Long-Term
Despite the brutal morning, Wall Street maintains confidence. Fourteen analysts rate the stock a Buy with one Hold. The consensus price target of $75.42 implies 122% upside from current levels.
That optimism depends on Janux addressing investor concerns. The company needs to generate more robust patient data. Clear answers about dosing protocols and Phase 3 timelines would help.
The clinical development process continues. JANX007 remains in dose optimization. The latest update included limited incremental patient information, frustrating those looking for clear progress indicators.
Execution risk for JANX007 has increased following this data release. The path forward requires demonstrating competitive differentiation against established treatments like Pluvicto.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
